Management Strategies for Liver Fibrosis
Management Strategies for Liver Fibrosis
复制标题
DOI：
10.5604/16652681.1226814
复制
发表时间：
2017-02-01
影响因子：
3.8
通讯作者：
Méndez-Sánchez, Nahum
中科院分区：
文献类型：
--
作者：
Altamirano-Barrera, Alejandra;Barranco-Fragoso, Beatriz;Méndez-Sánchez, Nahum
慢性肝损伤引起的肝纤维化是世界范围内发病率和死亡率的主要原因。在肝纤维化的原因中，病毒感染是最常见的（乙型和丙型肝炎）。此外，世界范围内的肥胖率加速了由非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）引起的肝损伤风险。肝纤维化也与饮酒、自身免疫性肝炎和慢性胆管病有关。肝细胞对炎症的反应在肝纤维化的生理病理中起着决定性的作用，它涉及到促炎性细胞和抗炎性细胞（如单核细胞和巨噬细胞）的募集。以及其他细胞因子和趋化因子的产生，它们通过激活促炎细胞来增加对肝星状细胞的刺激。本综述的目的是确定可用于治疗肝纤维化的治疗方案，以便在及时发现时预防进展。
Liver fibrosis resulting from chronic liver injury are major causes of morbidity and mortality worldwide. Among causes of hepatic fibrosis, viral infection is most common (hepatitis B and C). In addition, obesity rates worldwide have accelerated the risk of liver injury due to nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Also liver fibrosis is associated with the consumption of alcohol, or autoimmune hepatitis and chronic cholangiophaties. The response of hepatocytes to inflammation plays a decisive role in the physiopathology of hepatic fibrosis, which involves the recruitment of both pro- and anti-inflammatory cells such as monocytes and macrophages. As well as the production of other cytokines and chemokines, which increase the stimulus of hepatic stellate cells by activating proinflammatory cells. The aim of this review is to identify the therapeutic options available for the treatment of the liver fibrosis, enabling the prevention of progression when is detected in time.